Preparation and in vitro studies of fixed-dose tablet combination of repaglinide and metformin

被引：0
作者：
Sahin, Sinem [1 ]
Mesut, Burcu [2 ]
Durgun, M. Ezgi [2 ]
Ozcelik, Esher [3 ]
Ozsoy, Yildiz [2 ]
机构：
[1] Onko Kocsel Pharmaceut, Kocaeli, Turkey
[2] Istanbul Univ, Fac Pharm, Pharmaceut Technol Dept, Istanbul, Turkey
[3] Cibali Hlth & Social Secur Ctr, Istanbul, Turkey
来源：
ISTANBUL JOURNAL OF PHARMACY | 2021年 / 51卷 / 01期
关键词：
Fixed-Dose Tablet; Metformin; Repaglinide; TYPE-2; PHARMACOKINETICS; THERAPY; CARE;
D O I：
10.26650/IstanbulJPharm.2020.0070
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background and Aims: The study aimed to design a Fixed-dose tablet formulation of Metformine and Repaglinide. Methods: Wet granulation method was used to prepare tablet formulations. Characterization studies and dissolution studies were performed. Results: A stable formulation was developed according to the requirements of the pharmacopoeia criteria. This new formulsation dissolution results showed that Repaglinide and Metformin HCl dissolved more than 85% from film tablets at 15 minutes. Conclusion: Thus, an alternative product to the market product was developed.
引用
收藏
页码：26 / 34
页数：9
相关论文
共 50 条
[21]   Fixed-dose single tablet antidiabetic combinations [J].
Bailey, C. J. ;
Day, C. .
DIABETES OBESITY & METABOLISM, 2009, 11 (06) :527-533
[22]   Fixed combination of repaglinide and metformin in the management of type 2 diabetes [J].
Moses, Robert .
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2009, 2 :101-109
[23]   Effect of food and tablet-dissolution characteristics on the bioavailability of a linagliptin fixed-dose combination with metformin: evidence from two randomized trials [J].
Metzmann, Katrin ;
Schnell, David ;
Jungnik, Arvid ;
Ring, Arne ;
Theodor, Rudolf ;
Hohl, Kathrin ;
Meinicke, Thomas ;
Friedrich, Christian .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (07) :549-563
[24]   A fixed-dose combination of pioglitazone and metformin: a promising alternative in metabolic control [J].
Seufert, Jochen .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 :S39-S48
[25]   Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes [J].
Reynolds, Jonathan K. .
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2009, 2 :127-134
[26]   Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination [J].
Lee, Sang Won ;
Park, Sang-In ;
Lee, SeungHwan ;
Chung, Jae-Yong ;
Yu, Kyung-Sang .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (02) :117-124
[27]   Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food [J].
Weller, Stephen ;
Chen, Shuguang ;
Borland, Julie ;
Savina, Paul ;
Wynne, Brian ;
Piscitelli, Stephen C. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 66 (04) :393-398
[28]   An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of a sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects [J].
Chen, Xia ;
Zhao, Qian ;
Zhang, Jianyan ;
Liu, Tao ;
Jiang, Ji ;
Hu, Pei .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (09) :705-711
[29]   Linagliptin/Metformin Fixed-Dose Combination Treatment: A Dual Attack to Type 2 Diabetes Pathophysiology [J].
Chrysi Koliaki ;
John Doupis .
Advances in Therapy, 2012, 29 :993-1004
[30]   Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review [J].
Kedia, Rohit ;
Kulkarni, Supriya ;
Ross, Meredith ;
Shivaswamy, Vijay .
PATIENT PREFERENCE AND ADHERENCE, 2016, 10 :1999-2006
12345